Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation

CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.

Related Posts

Israel Adesanya Officially Announces Next Fight At UFC 305

risingforbes Jun 17, 2024  0  4

Inside Fashion’s Regenerative Cotton, And Brands Paying...

risingforbes Apr 10, 2025  0  0

The Founder's DNA: Are You Wired For Startup Life?

risingforbes Oct 29, 2024  0  1

Comments

Name

Email

Comment

Post Comment